apatorsen + carboplatin + gemcitabine

This is a combination therapy consisting of apatorsen, carboplatin, and gemcitabine. Apatorsen (OGX-427) is an antisense oligonucleotide designed to inhibit the production of heat shock protein 27 (Hsp27), a protein that helps cancer cells survive and resist treatment. By targeting Hsp27, apatorsen aims to disable cancer cell defenses and enhance the effectiveness of chemotherapy. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death. This combination has been investigated primarily in advanced cancers such as squamous cell lung cancer and metastatic bladder cancer. The rationale for combining these agents is to improve outcomes by overcoming resistance mechanisms associated with standard chemotherapy.